PPT-Switch to LPV/r + RAL

Switch to LPVr RAL KITE Study KITE Study switch to LPVr RAL Design Age 18 years HIV No previous virologi c failure to PIrbased ART HIV1 RNA lt 50 cml On stable 6 months 2 NRTI 3rd agent. of HIV Infection. Dual therapies without NRTIs. Jean-Guy Baril, MD. Clinique médicale du Quartier Latin. CHUM. This activity is supported by. an educational grant from:. Received consultant, investigator or speaker honoraria/grants from the following companies . r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . for . treatment monitoring. Nathan . Ford. Dept. of . HIV/AIDS. World Health . Organization. WHO ART guidelines evolution. Topic. 2002. 2003. 2006. 2010. 2013. When to start. CD4 ≤200. CD4 ≤ 200. QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Objective. Non inferiority of RAL QD: % HIV RNA < 40 c/mL by ITT, NC=F . (lower margin of the 2-sided 95% CI for the difference = - 10%, 90% power). RAL 1200 mg ** QD + . . Easier for HCW’s to prescribe for . all. ages. Easier for caregivers to administer to infants . and children. Easier for infants and children to adhere. Easier to manage supply chain. Target Product Profile for . M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA.  . 0-3 years. >3years and >10 kg.  . 1. LPV/r mono vs LPV/r ZDV/3TC MONARK. LPV/r QD vs BID. . M02-418. . M05-730. . A5073. LPV/r 3TC vs LPV/r 2 NRTI GARDEL. ATV/r vs FPV/r ALERT. ATV/r vs DRV/r ATADAR. FPV/r vs LPV/r KLEAN. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent (and other housekeeping items…). Miguel Román, . Pierre . Guillevic, Jaime . Nickeson. , Zhuosen Wang. with contributions from the CEOS-LPV Focus Area Leads. MODIS/VIIRS Science Team Meeting. : June 6-10, 2016 . 2020-02 Dr Laura Oyiengo. NATIONAL AIDS STI CONTROL PROGRAM. MOH. BACKGROUND. As a country with the fourth largest Pediatric HIV epidemic in the world, Pediatricians need to be involved in programming, decision making and management of children and adolescent living with HIV and also in PMTCT programming.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. Bob Harrington, MD. University of Washington . Presentation prepared by: . Presenter. Last Updated: . Date. Early Vs Deferred HAART . Strategic Timing of . AntiRetroviral. Treatment (START) Study. START: 2015. HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.